Antagonism of VEGF by Genetically Engineered Dendritic Cells Is Essential to Induce Antitumor Immunity against Malignant Ascites

@article{Sugiyama2011AntagonismOV,
  title={Antagonism of VEGF by Genetically Engineered Dendritic Cells Is Essential to Induce Antitumor Immunity against Malignant Ascites},
  author={Masahiko Sugiyama and Yoshihiro Kakeji and Shun-ichi Tsujitani and Yui Harada and Mitsuho Onimaru and Kumi Yoshida and Sakura Tanaka and Yasunori Emi and Masaru Morita and Yosuke Morodomi and Mamoru Hasegawa and Yoshihiko Maehara and Yoshikazu Yonemitsu},
  journal={Molecular Cancer Therapeutics},
  year={2011},
  volume={10},
  pages={540 - 549}
}
Malignant ascitis (MA) is a highly intractable and immunotherapy-resistant state of advanced gastrointestinal and ovarian cancers. Using a murine model of MA with CT26 colon cancer cells, we here determined that the imbalance between the VEGF-A/vascular permeability factor and its decoy receptor, soluble fms-like tryrosine kinase receptor-1 (sFLT-1), was a major cause of MA resistance to dendritic cell (DC)-based immunotherapy. We found that the ratio of VEGF-A/sFLT-1 was increased not only in… 
Suppression of vascular endothelial growth factor abrogates the immunosuppressive capability of murine gastric cancer cells and elicits antitumor immunity
TLDR
Results reveal an immunosuppressive role for VEGF in murine gastric cancer and gain resistance to re‐challenged parental tumors, which was attributed to an antitumor immunity response against parental MFC tumors.
Tumor-Altered Dendritic Cell Function: Implications for Anti-Tumor Immunity
TLDR
This review will highlight questions concerning tumor-altered DC function that remain unanswered, and address factors that have limited advances in the study of this phenomenon in order to focus future research efforts in the field on identifying strategies for interfering with tumor-associated DC dysfunction and improving DC-mediated anti-tumor immunity.
Vascular endothelial growth factor (VEGF) impairs the motility and immune function of human mature dendritic cells through the VEGF receptor 2‐RhoA‐cofilin1 pathway
TLDR
Results showed that VEGF can impair the migration capacity and immune function of mDCs through the RhoA‐cofilin1 pathway mediated by the V EGF receptor 2, suggesting impaired motility of m DCs by VEGf is one of the aspects of immune escape mechanisms of tumors.
The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model.
TLDR
The results support the indication of MBZ in combination with chemotherapeutic agents as a possible adjuvant therapy for the management/treatment of patients with advanced gastric cancer since MBZ is a drug of low cost with acceptable safety profile and reduced toxicity to normal cells.
Vascular endothelial growth factor suppresses dendritic cells function of human prostate cancer
TLDR
VEGF plays an important role in the inhibition of the maturation and function of dendritic cells, and this inhibition is gradually increased with an increasing malignant degree of PCa.
Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency
Oncolytic paramyxoviruses include some strains of Measles, Mumps, Newcastle disease, and Sendai viruses. All these viruses are well equipped for promoting highly specific and efficient malignant cell
Cell transfer‐based immunotherapies in cancer: A review
TLDR
This review examines the recent advances in CTT for the management of various malignancies and concludes that adoptive cell transfer, where the lymphocytes isolated from either a donor or the patient are modified ex vivo and reinfused to target malignant cells, is a viable treatment modality.
Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study)
TLDR
Sendai virus injections could be safe and efficient for the treatment of dogs affected by mastocytomas, and the need of further studies for finding optimal schemes and schedules for this kind of therapy is suggested.
Interleukin-4 and granulocyte-macrophage colony-stimulating factor mediates the upregulation of soluble vascular endothelial growth factor receptor-1 in RAW264.7 cells-a process in which p38 mitogen-activated protein kinase signaling has an important role.
TLDR
IL-4 and GM-CSF increased sVEGFR1 levels, but did not significantly effect VEGF expression, and led to the antiangiogenesis properties of monocytes.
Cell Transfer Therapy for Cancer: Past, Present, and Future
TLDR
Recent advances in the exploration of dendritic cells, NK cells, and T cells for the treatment of human cancer cells are overviewed.
...
1
2
...

References

SHOWING 1-10 OF 41 REFERENCES
Sustained and NK/CD4+ T Cell-Dependent Efficient Prevention of Lung Metastasis Induced by Dendritic Cells Harboring Recombinant Sendai Virus1
TLDR
These results are the first demonstration of efficient inhibition of lung metastasis via bolus administration of virally activated DCs that was sustained and NK/CD4+ cell-dependent, and may suggest a potentially new mechanism of DC-based immunotherapy for advanced malignancies.
Induction of Efficient Antitumor Immunity Using Dendritic Cells Activated by Recombinant Sendai Virus and Its Modulation by Exogenous IFN-β Gene1
TLDR
Results indicate that rSeV is a new and powerful tool as an immune booster for DC-based cancer immunotherapy that can be significantly modified by IFN-β, and SeV/DC, therefore, warrants further investigation as a promising alternative for cancer Immunotherapy.
Complete elimination of established neuroblastoma by synergistic action of γ-irradiation and DCs treated with rSeV expressing interferon-β gene
TLDR
A preclinical efficacy study to examine murine models and indicate that the combination of ts-rSeV/dF-mIFNβ-DCs with γ-irradiation is a hopeful strategy for the treatment of intractable neuroblastomas, warranting further investigation in the clinical setting.
A novel function for dendritic cell: clearance of VEGF via VEGF receptor-1.
TLDR
A novel function of DCs is highlighted and a better understanding of the DC-VEGF interaction is allowed and is highlighted to demonstrate that Cy3-labeled VEGF could be internalized by DCs specifically and efficiently.
Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen.
TLDR
It is found that ex vivo infection of immature dendritic cells (DCs) with SeV demonstrates their spontaneous maturation and activation, indicating that rSeV could be a powerful immune booster for DC-based cancer immunotherapy that is worth investigating further.
Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells.
TLDR
This is the first demonstration that non-transmissible SeV vector, SeV/dF, could be a DC-activator; DC/SeV/ dF-based cancer immunotherapy may, therefore, warrant further investigation.
Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor.
TLDR
It is concluded that Ad-mediated in vivo regional delivery of a secreted form of the extracellular domain of the flt-1 VEGF receptor can effectively inhibit regional tumor growth, a strategy that may provide a means to control tumor growth within the treated organ without the risk of systemic antiangiogenesis.
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
TLDR
It is shown that human cancer cell lines release a soluble factor or factors that dramatically affect DC maturation from precursors without affecting the function of relatively mature DCs, and one factor responsible for these effects was identified as vascular endothelial growth factor (VEGF).
Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis
TLDR
Adenoviral delivery of human soluble VEGF receptor type 1 significantly suppressed disease activity in CIA, and these results support the concept that V EGF blockade may be an effective therapeutic adjunct for the treatment of RA.
Essential Role of PDGFRα-p70S6K Signaling in Mesenchymal Cells During Therapeutic and Tumor Angiogenesis In Vivo
TLDR
It is demonstrated that p70S6K inhibitor rapamycin (RAPA) targets mesenchymal cells to shut down the sustained expression of vascular endothelial growth factor and hepatocyte growth factor, via silencing of the PDGFRα-p70S 6K pathway.
...
1
2
3
4
5
...